Amgen Inc. Q3 2026 Earnings Recap

Amgen’s shares rose 3.7% after the company reported 8% revenue growth and 27% growth from its six key growth drivers. Repatha, EVENITY and TEZSPIRE led the commercial performance, while the transcript excerpt does not provide updated financial guidance.

Key Takeaways

• Third-quarter revenue grew 8% year over year to $10.4 billion; product sales also grew 8%.
• The six key growth drivers grew 27% and accounted for more than 70% of product sales. Seventeen products delivered double-digit sales growth, and 17 were annualizing above $1 billion based on third-quarter sales.
• Repatha sales rose 37% to $1.1 billion; EVENITY sales rose 39% to $751 million; TEZSPIRE sales rose 43% to $538 million.
• Amgen generated $3.7 billion in free cash flow, increased R&D investment 11% year over year and spent another $600 million on capital expenditures.
• The company reported positive Phase III results for IMDELLTRA, TEZSPIRE in eosinophilic esophagitis and dazodalibep. The excerpt gives no detailed results or updated guidance.